Dorzolamide hydrochloride: A topically active, carbonic anhydrase inhibitor for the treatment of glaucoma

Drugs of Today

Volumn 33, Issue 5, 1997, Pages 283-298

  Sugrue, Michael F ^a   Harris, Alon ^b   Adamsons, Ingrid ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; ETHOXZOLAMIDE; METHAZOLAMIDE; PILOCARPINE; PLACEBO; TIMOLOL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXCRETION; DRUG MIXTURE; DRUG POTENCY; DRUG TOLERANCE; DRUG URINE LEVEL; ENZYME INHIBITION; ERYTHROCYTE LEVEL; GLAUCOMA; GUINEA PIG; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; NORMAL HUMAN; QUALITY OF LIFE; RABBIT; RAT; REVIEW; STATISTICAL ANALYSIS; TOPICAL DRUG ADMINISTRATION;

EID: 0030751115     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1997.33.5.430476     Document Type: Review

References (63)

1. Liesegang, T.J. Glaucoma: Changing concepts and future directions. Mayo Clin Proc 1996, 71: 689-94.
2. Quigley, H.A. Number of people with glaucoma worldwide. Br J Opthalmol 1996, 80: 389-93.
3. Orgul, S., Flammer, J., Gasser, P. Female preponderance in normal-tension glaucoma. Ann Ophthalmol 1995, 27: 355-9.
4. Van Buskirk, E.M., Cioffi, G.A. Glaucomatous optic neuropathy. Am J Ophthalmol 1992, 113: 447-52.
5. Wistrand, P.J. Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand 1951, 24: 144-8.
6. Wistrand, P.J., Garg, L.C. Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Opthalmol Vis Sci 1979, 18: 802-6.
7. Dobbs, P.C., Epstein, D.L., Anderson, P.J. Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci 1979, 18: 867-70.
8. Becker, B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol 1954, 37: 13-4.
9. Epstein, D.L., Grant, W.M. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol 1977, 95: 1378-82.
10. Maren, T.H. The development of topical carbonic anhydrase inhibitors. J Glaucoma 1995, 4: 49-62.
11. Lippa, E.A., von Denffer, H.A., Hofmann, H.M., Brunner-Ferber, F.L. Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor. Arch Ophthalmol 1988, 106: 1694-6.
12. Bron, A.M., Lippa, E.A., Hofmann, H.M. et al. MK-927: A topically effective carbonic anhydrase inhibitor in patients. Arch Ophthalmol 1989, 107: 1143-6.
13. Sugrue, M.F., Mallorga, P., Schwam, H., Baldwin, J.J., Ponticello, G.S. A comparison of L-671, 152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 1990, 9: 607-15.
14. Sly, W.S., Hu, P.Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995, 64: 375-401.
15. Wistrand, P.J., Schenholm, M., Lonnerholm, G. Carbonic anhydrase isoenzymes CA-I and CA-II in the human eye. Invest Ophthalmol Vis Sci 1986, 27: 419-28.
16. Hageman, G.S., Zhu, X.L., Waheed, A., Sly, W.S. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci USA 1991, 88: 2716-20.
17. Wolfensberger, T.J., Mahieu, I., Jarvis-Evans, J. et al. Membrane-bound carbonic anhydrase in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1994, 35: 3401-7.
18. Krupin, T., Sly, W.S., Whyte, M.P., Dodgson, S.J. Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. Am J Ophthalmol 1985, 99: 396-9.
19. Smith, G.M., Alexander, R.S., Christianson, D.W. et al. Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci 1994, 3: 118-25.
20. Maren, T.H., Wynns, G.C., Wistrand, P.J. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme. Mol Pharmacol 1993, 44: 901-5.
21. Sugrue, M.F., Gautheron, P., Grove, J. et al. MK-927: A topically active ocular hypotensive carbonic anhydrase inhibitor. J Ocular Pharmacol 1990, 6: 9-22.
22. Sugrue, M.F. Review: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocular Pharmacol Ther 1996, 12: 363-76.
23. Kuang, K., Xu, M., Koniarek, J.P., Fischbarg, J. Effects of ambient bicarbonate, phosphate and carbonic anhydrase inhibitors on fluid transport across rabbit corneal endothelium. Exp Eye Res 1990, 50: 487-93.
24. Wang, R.-F., Serle, J.B., Podos, S.M., Sugrue, M.F. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671, 152 in glaucomatous monkeys. Arch Ophthalmol 1990, 108: 511-3.
25. Lee, P.-Y., Podos, S.M., Howard-Williams, J.R., Severin, C.H., Rose, A.D., Siegel, M.J. Pharmacological testing in the laser-induced monkey glaucoma model. Curr Eye Res 1985, 4: 775-81.
26. Wang, R.-F., Serle, J.B., Podos, S.M., Sugrue, M. F. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol 1991, 109: 1297-9.
27. Vareilles, P., Lotti, V.J. Effect of timolol on aqueous humor dynamics in the rabbit. Ophthalmic Res 1981, 13: 72-9.
28. Friedland, B.R., Maren, T.H. Carbonic anhydrase: Pharmacology of inhibitors and treatment of glaucoma. In: Pharmacology of the Eye. Sears, M.L. (Ed.). Springer-Verlag: Berlin 1984, 279-309.
29. Camras, C.B., Podos, S.M. The role of endogenous prostaglandins in clinically used and investigational therapy. In: The Ocular Effects of Prostaglandins and Other Eicosanoids. Bito, L.Z., Stjernschantz, J. (Eds.). Alan R. Liss, Inc: New York 1989, 459-75.
30. Sugrue, M.F., O'Neill-Davis, L. The effect of cyclooxygenase inhibition on the ocular hypotensive action of topical carbonic anhydrase inhibitors in rabbits. J Ocular Pharmacol 1991, 7: 201-11.
31. Gordon, L.R., Bailly, Y., Durand-Cavagna, G., Delort, P., Peter, C.P. Preclinical ocular irritation findings with dorzolamide hydrochloride. J Toxicol Cut Ocular Toxicol 1997, 16: 9-17.
32. Friedland, B.R., Maren, T.H. The relation between carbonic anhydrase activity and ion transport in elasmobranch and rabbit lens. Exp Eye Res 1981, 33: 545-61.
33. Magnusson, B., Kligman, A.M. The identification of contact allergens by animal assay: The guinea pig maximization test. J Invest Dermatol 1969, 52: 268-76.
34. Durand-Cavagna, G., Delort, P., Gordon, L.R., Peter, C.P., Smith, R.L. Cross sensitivity reactions among carbonic anhydrase inhibitors in the guinea pig. J Toxicol Cut Ocular Toxicol 1995, 14: 63-73.
35. Conroy, C.W., Schwam, H., Maren, T.H. The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine. Drug Metab Dispos 1984, 12: 614-8.
36. Hasegawa, T., Hara, K., Kenmochi, T., Hata, S. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab Dispos 1994, 22: 916-21.
37. Ponticello, G.S., Sugrue, M.F., Plazonnet, B., Durand-Cavagna, G. Dorzolamide: A forty year wait: from an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. In: Integration of Pharmaceutical Discovery and Development: Case Histories. Borchardt, R.T., Freidinger, R.M., Sawyer, T., Smith, P. (Eds.). Plenum: New York, in press.
38. Hasegawa, T., Hara, K., Hata, S. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos 1994, 22: 377-82.
39. Wong, B.K., Bruhin, P.J., Barrish, A., Lin, J.H. Nonlinear dorzolamide pharmacokinetics in rats: Concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Drug Metab Dispos 1996, 24: 659-63.
40. Wilkerson, M., Cyrlin, M., Lippa, E.A. et al. Four-week safety and efficary study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993, 111: 1343-50.
41. Maren, T.H. Carbonic anhydrase: Chemistry, physiology, and inhibition. Physiol Rev 1967, 47: 595-781.
42. Strahlman, E., Tipping, R., Vogel, R. and The Dorzolamide Dose-Response Study Group. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996, 122: 183-94.
43. Biollaz, J., Munafo, A., Buclin, T. et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995, 47: 453-60.
44. Harris, A., Sergott, R.C., Spaeth, G.L., Katz, J.L., Shoemaker, U.A., Martin, B.J. Color Doppler analysis of ocular vessel blood velocity in normal-tension glaucoma. Am J Ophthalmol 1994, 118: 642-9.
45. Tielsch, J.M., Katz, J., Sommer, A., Quigley, H.A., Javitt, J.C. Hypertension, perfusion pressure, and primary open-angle glaucoma. Arch Ophthalmol 1995, 113: 216-21.
46. 2 dependence of retinal arterial and capillary blood velocity. Acta Ophthalmol Scand 1995, 73: 421-4.
47. Rassam, S.M.B., Patel, V., Kohner, E.M. The effect of acetazolamide on the retinal circulation. Eye 1993, 7: 697-702.
48. Harris, A., Arend, O., Arend, S., Martin, B. Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol Scand 1996, 74: 569-72.
49. Grunwald, J.E., Zinn, H. The acute effect of oral acetazolamide on macular blood flow. Invest Ophthalmol Vis Sci 1992, 33: 504-7.
50. Wolf, S., Arend, O., Sponsel, W.E. Retinal hemodynamics using scanning laser ophthalmoscopy and hemorrheology in chronic open-angle glaucoma. Ophthalmology 1993, 100: 1561-6.
51. Strahlman, E., Tipping, R., Vogel, R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995, 113: 1009-16.
52. Tarkkanen, A. Treatment of chronic open-angle glaucoma associated with pseudoexfoliation. Acta Ophthalmol 1965, 43: 514-23.
53. Olivius, E., Thorburn, W. Prognosis of glaucoma simplex and glaucoma capsulare: A comparative study. Acta Ophthalmol Scand 1978, 56: 921-34.
54. Brooks, A.M.V., Gillies, W.E. The presentation and prognosis of glaucoma in pseudoexfoliation of the lens capsule. Ophthalmology 1988, 95: 271-6.
55. Heijl, A., Strahlman, E., Sverrisson, Th., Brinchman-Hansen, O., Puustjarvi, T., Tipping, R. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 1997, 104: 137-42.
56. Chandler, P.A. (Ed.). Chandler and Grant's Glaucoma, 3rd Ed. Lea & Febiger: Philadelphia 1986, 141-7.
57. Strahlman, E.R., Vogel, R., Tipping, R., Clineschmidt, C.M. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996, 103: 1283-93.
58. Ritch, R., Shields, M.B., Krupin, T. (Eds.). The Glaucomas. CV Mosby Co.: St. Louis 1989, 517-8.
59. Webster, A.R., Luff, A.J., Canning, C.R., Elkington, A.R. The effect of pilocarpine on the glaucomatous visual field. Br J Ophthalmol 1993, 77: 721-5.
60. Laibovitz, R., Strahlman, E.R., Barber, B.L., Strohmaier K.M. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995, 4: 306-13.
61. Barber, B.L., Strahlman, E.R., Laibovitz, R.A. et al. Validation of a new questionnaire for Comparison of Ophthalmic Medications for Tolerability (COMTol) in the treatment of open-angle glaucoma. Ophthalmology, in press.
62. Hutzelmann, J., Polis, A., Adamsons, I. A comparison of the tolerability and efficacy of dorzolamide and acetazolamide as adjunctive therapy to timolol. Br J Ophthalmol, submitted.
63. Lass, J.H., Khosrof, S., Laurence, J.K., Ghosh, K., Adamsons, I. Corneal safety of dorzolamide, timolol, and betaxolol after 1 year of therapy. Invest Ophthalmol Vis Sci, submitted.